Source comparison
CJC-1295 No DAC & Ipamorelin: Sleep Study Comparison
Understanding the practical differences between peptide protocols, administration variables, and expected outcomes helps researchers and clinicians design studies with realistic endpoints and controlled variables. CJC-1295 No DAC + Ipamorelin 100–200 mcg CJC +
This comparison does not assign a generated winner or score.
- Understanding the practical differences between peptide protocols, administration variables, and expected outcomes helps researchers and clinicians design studies with realistic endpoints and controlled variables.
- CJC-1295 No DAC + Ipamorelin
- 100–200 mcg CJC + 200–300 mcg Ipa
- 30–60 min pre-sleep
- Stage 3 NREM duration ↑ 22–31%, REM onset latency ↓ 18 min average
- Improved sleep continuity, reduced WASO episodes, enhanced subjective sleep quality
- Gold standard for sleep architecture restoration without cortisol elevation. Synergistic receptor activation produces 3–5× growth hormone amplitude vs monotherapy
- CJC-1295 No DAC alone
- 200–300 mcg
- Modest stage 3 NREM extension (12–18%), inconsistent REM effects
- Fewer injection site reactions, lower cost
- Limited efficacy without ghrelin pathway co-stimulation. GHRH receptor activation alone produces subthreshold growth hormone pulses in many adults over 40
- Ipamorelin alone
- 300–500 mcg
- Subjective quality improvement, minimal objective architecture changes
- Well-tolerated, no prolactin elevation
- Insufficient growth hormone amplitude to meaningfully alter polysomnography markers unless dosed at upper range (500+ mcg), which increases cost without proportional benefit
- MK-677 (oral ghrelin agonist)
- 12.5–25 mg orally
- 60–90 min pre-sleep
- Stage 3 NREM ↑ 15–20%, continuous elevation (not pulsatile)
- Oral administration, 24-hour half-life
- Non-pulsatile growth hormone elevation disrupts natural circadian rhythm. Effective for sleep but increases appetite and insulin resistance risk with chronic use
- GHRP-6 + CJC-1295 No DAC
- 100 mcg GHRP-6 + 100–200 mcg CJC
- Stage 3 NREM ↑ similar to Ipamorelin stack, but with significant appetite stimulation
- Strong growth hormone response
- GHRP-6 lacks selectivity. Stimulates cortisol, prolactin, and ghrelin pathways indiscriminately, causing hunger and potential sleep fragmentation in responsive individuals
- CJC-1295 No DAC combined with Ipamorelin remains the most selective and well-tolerated peptide stack for sleep architecture optimization. The dual-pathway mechanism produces physiologically appropriate pulsatile growth hormone secretion without elevating stress hormones or appetite-regulating peptides that counteract sleep quality. Monotherapy protocols can work but typically require higher doses or produce inconsistent results. Oral secretagogues like MK-677 improve sleep but disrupt metabolic parameters with prolonged use, making them better suited for short-term interventions rather than chronic sleep restoration.